Skip to main content

Table 7 Probabilistic sensitivity analysis results according to PFS and OS. Amounts are presented in MXN pesos

From: Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

TKI Mean total cost Incremental Cost Effectiveness Incremental Effectiveness ICER
Progression Free Survival (PFS)
 Gefitinib $161,781.47 8.180
 Erlotinib $218,411.28 $56,629.81 6.701 −1.48 Dominated
 Afatinib $347,853.28 $129,442.00 9.457 1.28 $101,363.54
Overall Survival (OS)
 Gefitinib $157,891.46 27.098
 Erlotinib $207,416.43 $49,524.98 21.774 −5.32 Dominated
 Afatinib $347,423.61 $140,007.18 37.095 10.00 $14,004.90